Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Sartorius Stedim Biotech Expands Portfolio by Adding Cell Culture Media

Published: Friday, December 21, 2012
Last Updated: Friday, December 21, 2012
Bookmark and Share
Sartorius Stedim Biotech assumes global sales and marketing of media and buffer solutions for biopharmaceutical manufacture.

Sartorius Stedim Biotech (SSB), a leading international pharmaceutical and biotech supplier, today announced a substantial expansion of its product array in the cell culture range. The company signed a cooperation agreement with the Swissbased life science group Lonza on long-term, global collaboration in the field of cell culture media. Cell culture media are growth substances and nutrients for cells or microorganisms and are required in every biopharmaceutical manufacturing process.

The cooperation agreement provides that SSB will assume global sales and marketing of Lonza’s media and buffers used in the manufacture of protein-based therapeutics and vaccines, while Lonza will continue to carry out development, manufacture and logistics operations for these products. New product development will be mutually performed. The cell culture media, which are usually sold in liquid or powder form to biopharmaceutical customers, are to be successively converted to packaged forms as ready-to-use, prefilled SSB sterile single-use bags. Furthermore, Lonza and SSB have agreed that these cell culture media will be sold under both brands in a co-branding arrangement.

In fiscal 2011, Lonza generated revenue of around 20 million euros with its cell culture media business. SSB will take over Lonza’s commercial team of approximately 15 media specialists. Both parties have agreed not to disclose further contractual conditions.

Lonza’s cell culture media represent an ideal fit with the portfolio of products supplied by Sartorius Stedim Biotech, which already offers bioreactors and single-use bags and containers as key components for cell cultivation. “I am very pleased that we will now be adding a market-leading, high-quality array of media and buffers to our product offering,” commented SSB’s Member of the Board of Directors, Reinhard Vogt. “Just like our single-use bags and bioreactors, culture media are critical to the success of safe and efficient manufacture of drug materials. The demand for ready-to-use and innovative products is accordingly high. In 2 the manufacture of biologicals, our customers will benefit from obtaining fully integrated single-use solutions for their entire cell culture process all from a single source.”

“For Lonza this agreement provides great upside potential as it will allow us to capture additional value from our Media Business in the form of additional revenue leading to higher capacity utilization”, comments Lukas Utiger, COO of Lonza Bioscience. “Lonza and Sartorius are a great fit as both partners bring complementary strengths to the benefit of our customers.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sartorius Stedim Biotech and GE Healthcare Sign Worldwide OEM Supply Agreement
Expands GE’s start-to-finish offering for cost efficient manufacture of biopharmaceuticals.
Tuesday, September 01, 2015
Miriam Monge to Join Sartorius Stedim Biotech
Company appoints Miriam Monge as director of marketing for integrated solutions.
Wednesday, August 27, 2014
Sartorius Stedim Announces Offer to Acquire TAP Biosystems
Sartorius Stedim Biotech to further expand its portfolio of single-use fermentors.
Tuesday, October 08, 2013
Sartorius Appoints Senior Vice President
Appointment of Stefan Schlack as Senior Vice President of marketing.
Thursday, October 25, 2012
SSB and Bosch Announce Global Collaboration
Agreement covers the mutual design and development of single-use filling solutions.
Thursday, June 21, 2012
SSB and Refine Technology Announce Cooperation
Development of a robust, easy-to-use platform for high-density cell cultivation.
Tuesday, January 24, 2012
SSB and G-Con Manufacturing Announce Global Collaboration
Collaboration will support faster and more flexible facility construction and shortened time to market.
Thursday, January 19, 2012
Sartorius Stedim Biotech and GE Healthcare Life Sciences Sign Cross-Licensing Agreement
Agreement covers intellectual property relating to biopharmaceutical manufacturing technologies.
Monday, September 12, 2011
SSB and Südpack Medica AG Sign Exclusive Cooperation Agreement
Südpack and SSB cooperate in the manufacture of plastic film.
Friday, June 17, 2011
Sartorius Stedim Biotech and RAUMEDIC Sign Partnership Agreement
SSB’s product portfolio to be extended by tubing and polymer components.
Friday, May 20, 2011
Scientific News
13 Ways to Stop an Unseen Force from Disrupting Weighing
Download a free Mettler Toledo paper to discover how to halt static’s negative effects before the next weigh-in.
Inroads Against Leukemia
Potential for halting disease in molecule isolated from sea sponges.
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
Milestone Single-Biomolecule Imaging Technique May Advance Drug Design
The first nanometer resolved image of individual tobacco mosaic virions shows the potential of low-energy electron holography for imaging biomolecules at a single particle level; a milestone in structural biology and a potential new tool for drug design.
Researchers Discover A New Mechanism of Proteins to Block HIV
Certain IFITM proteins block and inhibit cell-to-cell transmission of HIV.
Opening the Door to Safer, More Precise Cancer Therapies
New method regulates when, and how strongly, cancer-killing therapeutic T cells are activated.
Vaccination On The Horizon For Severe Viral Infection Of The Brain
Researchers from the University of Zurich and the University Hospital Zurich reveal possible new treatment methods for a rare, usually fatal brain disease.
‘Immune Camouflage’ may Explain H7N9 Influenza Vaccine Failure
The study is published in Human Vaccines & Immunotherapeutics.
Revolutionary Gene-editing Technique to Stop AIDS Virus in Its Tracks
UNLV personalized medicine researchers seeking patent on potential HIV cure. Their technique uses a plant protein widely used in agriculture industry.
Drug Disarms Deadly C. difficile Bacteria Without Destroying Healthy Gut Flora
A drug that blocks the intestinal pathogen without killing resident, beneficial microbes may prove superior to antibiotics, currently the front-line treatment for the infection.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos